Lead- and drug-like compounds: The rule-of-five revolution

Drug Discovery Today: Technologies

Volumn 1, Issue 4, 2004, Pages 337-341

  Lipinski, Christopher A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CENTRAL NERVOUS SYSTEM AGENTS; DRUG; GLYCOPROTEIN P;

BINDING AFFINITY; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG INDUSTRY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HYDROGEN BOND; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW;

EID: 13244266921     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2004.11.007     Document Type: Review

References (45)

1. C.A. Lipinski et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3-25
2. T.I. Oprea Property distribution of drug-related chemical databases J. Comput. Aided Mol. Des. 14 2000 251-264
3. M.P. Bradley An overview of the diversity represented in commercially-available databases Mol. Divers. 5 2002 175-183
4. D.F. Veber et al. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 45 2002 2615-2623
5. P.R. Andrews et al. Functional group contributions to drug-receptor interactions J. Med. Chem. 27 1984 1648-1657
6. T. Fichert et al. A structure-permeability study of small drug-like molecules Bioorg. Med. Chem. Lett. 13 2003 719-722
7. G.W. Bemis and M.A. Murcko The properties of known drugs. 1. Molecular frameworks J. Med. Chem. 39 1996 2887-2893
8. G.W. Bemis and M.A. Murcko Properties of known drugs. 2. Side chains J. Med. Chem. 42 1999 5095-5099
9. T.I. Oprea et al. Pharmacokinetically based mapping device for chemical space navigation J. Comb. Chem. 4 2002 258-266
10. H. Matter et al. Computational approaches towards the rational design of drug-like compound libraries Comb. Chem. High Throughput Screen. 4 2001 453-475
11. I. Muegge et al. Simple selection criteria for drug-like chemical matter J. Med. Chem. 44 2001 1841-1846
12. I. Muegge Selection criteria for drug-like compounds Med. Res. Rev. 23 2003 302-321
13. R.M. Brunne et al. Virtual compound libraries and molecular modelling In Handbook of Combinatorial Chemistry (Vol. 2) (K.C. Nicolaou R. Hanko W. Hartwig eds.) 2002 761-783
14. S. Rose and A. Stevens Computational design strategies for combinatorial libraries Curr. Opin. Chem. Biol. 7 2003 331-339
15. A.A. Patchett and R.P. Nargund Privileged structures - an update Ann. Rep. Med. Chem. 35 2000 289-298 (Chapter 26)
16. R.W. DeSimone et al. Privileged structures: Applications in drug discovery Comb. Chem. High Throughput Screen. 7 2004 473-493
17. B.A. Tounge and C.H. Reynolds Defining privileged reagents using subsimilarity comparison J. Chem. Inf. Comput. Sci. 44 2004 1810-1815
18. G.M. Rishton Reactive compounds and in vitro false positives in HTS Drug Discov. Today 2 1997 382-384
19. M.C. Wenlock et al. A comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 46 2003 1250-1256
20. J.F. Blake Examination of the computed molecular properties of compounds selected for clinical development BioTechniques Suppl. 2003 16-20
21. J. Askenash The rule of five revisited Preclinica 2 2004 92
22. W.M. Pardridge Log(BB), PS products and in silico models of drug brain penetration Drug Discov. Today 9 2004 392-393
23. D.E. Clark In silico prediction of blood-brain barrier permeation Drug Discov. Today 8 2003 927-933
24. J. Kelder et al. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res. 16 1999 1514-1519
25. U. Norinder and M. Haeberlein Computational approaches to the prediction of the blood-brain distribution Adv. Drug Deliv. Rev. 54 2002 291-313
26. W.M. Pardridge Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain Curr. Opin. Drug Discov. Dev. 6 2003 683-691
27. M. Adenot et al. Blood-brain barrier permeation models: Discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates J. Chem. Inf. Comput. Sci. 44 2004 239-248
28. K.M.M. Doan et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs J. Pharmacol. Exp. Ther. 303 2002 1029-1037
29. F. Faassen et al. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs Int. J. Pharm. 263 2003 113-122
30. M. Adenot and R. Lahana Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates J. Chem. Inf. Comput. Sci. 44 2004 239-248
31. G.F. Ecker and C.R. Noe In silico prediction models for blood-brain barrier permeation Curr. Med. Chem. 11 2004 1617-1628
32. K.R. Horspool and C.A. Lipinski Advancing new drug delivery concepts to gain the lead Drug Deliv. Technol. 3 2003 34-46
33. M. Vieth et al. Characteristic physical properties and structural fragments of marketed oral drugs J. Med. Chem. 47 2004 224-232
34. A. Tronde et al. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: Structure-absorption relationships and physicochemical profiling of inhaled drugs J. Pharm. Sci. 92 2003 1216-1233
35. T.I. Oprea et al. Is there a difference between leads and drugs? A historical perspective J. Chem. Inf. Comput. Sci. 41 2001 1308-1315
36. E. Jacoby et al. Design of small molecule libraries for NMR screening and other applications in drug discovery Curr. Top. Med. Chem. 3 2003 11-23
37. C.A. Lepre et al. Applications of SHAPES screening in drug discovery Comb. Chem. High Throughput Screen. 5 2002 583-590
38. C.A. Lepre Strategies for NMR screening and library design Methods Princ. Med. Chem. 16 2003 391-415 (BioNMR in Drug Research)
39. R. Carr and H. Jhoti Structure-based screening of low-affinity compounds Drug Discov. Today 7 2002 522-527
40. A.M. Davis et al. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design Angew. Chem. Int. Ed. 42 2003 2718-2736
41. M. Congreve et al. A 'rule of three' for fragment-based lead discovery? Drug Discov. Today 8 2003 876-877
42. M.H. Hann et al. T.I. Oprea Pursuing the leadlikeness concept in pharmaceutical research Curr. Opin. Chem. Biol. 8 2004 255-263
43. T.I. Oprea Current trends in lead discovery: Are we looking for the appropriate properties? Mol. Divers. 5 2002 199-208
44. J.R. Proudfoot Drugs, leads, and drug-likeness: An analysis of some recently launched drugs Bioorg. Med. Chem. Lett. 12 2002 1647-1650
45. C.A. Lipinski Compound properties and drug quality In C.G. Wermuth Practice of Medicinal Chemistry 2nd edn 2003 341-349